The COVID-19 pandemic has had a significant impact on various aspects of healthcare, including the practice of allogeneic stem cell transplantation. In this article, we will explore the conceptual considerations and survey findings on the use of fresh and frozen grafts for allogeneic stem cell transplantation during the pandemic, as shared by the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working Party (CTIWP) in Bone Marrow Transplantation.
Allogeneic stem cell transplantation is a crucial treatment option for patients with hematological malignancies and other disorders. It involves the transfer of stem cells from a healthy donor to a recipient, with the aim of replacing the recipient’s diseased or damaged cells. The success of this procedure depends on various factors, including the quality of the graft used.
Traditionally, fresh grafts have been preferred for allogeneic stem cell transplantation due to their higher cell viability and lower risk of complications. However, the COVID-19 pandemic has posed unique challenges to the procurement and transportation of fresh grafts. Travel restrictions, reduced availability of donors, and concerns about potential viral transmission have led to a reevaluation of the use of fresh grafts.
To gain insights into the current practices and opinions regarding fresh and frozen grafts during the pandemic, the EBMT IDWP and CTIWP conducted a survey among transplant centers across Europe. The survey aimed to assess the impact of COVID-19 on graft selection and to identify any changes in practice.
The survey results revealed that there has been a significant shift towards the use of frozen grafts during the pandemic. This change is primarily driven by concerns about viral transmission and logistical challenges associated with procuring fresh grafts. Frozen grafts offer several advantages in this context, including easier transportation, longer storage times, and reduced risk of viral contamination.
However, it is important to note that the use of frozen grafts is not without its limitations. The freezing and thawing process can lead to a decrease in cell viability and functionality, potentially affecting the success of the transplantation. Additionally, the long-term effects of using frozen grafts on patient outcomes are still not fully understood.
To address these concerns, the survey also highlighted the need for standardized protocols and guidelines for the procurement, processing, and storage of frozen grafts. This would ensure consistency in graft quality and minimize the risk of complications. Furthermore, ongoing research is necessary to evaluate the long-term outcomes of using frozen grafts and to identify any potential differences compared to fresh grafts.
In conclusion, the COVID-19 pandemic has necessitated a reevaluation of the practice of allogeneic stem cell transplantation, particularly regarding the use of fresh and frozen grafts. The survey conducted by the EBMT IDWP and CTIWP provides valuable insights into the current practices and considerations in this area. While the use of frozen grafts has increased during the pandemic, further research and standardization are needed to optimize graft selection and ensure the best possible outcomes for patients undergoing allogeneic stem cell transplantation.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Automotive / EVs, Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- ChartPrime. Elevate your Trading Game with ChartPrime. Access Here.
- BlockOffsets. Modernizing Environmental Offset Ownership. Access Here.
- Source: Plato Data Intelligence.
- Source Link: https://platohealth.ai/fresh-or-frozen-grafts-for-allogeneic-stem-cell-transplantation-conceptual-considerations-and-a-survey-on-the-practice-during-the-covid-19-pandemic-from-the-ebmt-infectious-diseases-working-party-id/